578 related articles for article (PubMed ID: 29086702)
21. JAK-mutant myeloproliferative neoplasms.
Levine RL
Curr Top Microbiol Immunol; 2012; 355():119-33. PubMed ID: 21823028
[TBL] [Abstract][Full Text] [Related]
22. JAK2 mutation-related disease and thrombosis.
Vannucchi AM; Guglielmelli P
Semin Thromb Hemost; 2013 Jul; 39(5):496-506. PubMed ID: 23633193
[TBL] [Abstract][Full Text] [Related]
23. Analysis of JAK2V617F mutation in Jordanian patients with myeloproliferative neoplasms.
Jaradat SA; Khasawneh R; Kamal N; Matalka I; Al-Bishtawi M; Al-Sweedan S; Ayesh MH
Hematol Oncol Stem Cell Ther; 2015 Dec; 8(4):160-6. PubMed ID: 26256826
[TBL] [Abstract][Full Text] [Related]
24. JAK2 V617F mutation prevalence in myeloproliferative neoplasms in Pernambuco, Brazil.
da Silva RR; Domingues Hatzlhofer BL; Machado CG; Lima AS; de Albuquerque DM; dos Santos MN; Fertrin KY; Costa FF; Araújo Ada S; Bezerra MA
Genet Test Mol Biomarkers; 2012 Jul; 16(7):802-5. PubMed ID: 22304488
[TBL] [Abstract][Full Text] [Related]
25. The expression of Death Inducer-Obliterator (DIDO) variants in Myeloproliferative Neoplasms.
Berzoti-Coelho MG; Ferreira AF; de Souza Nunes N; Pinto MT; Júnior MC; Simões BP; Martínez-A C; Souto EX; Panepucci RA; Covas DT; Kashima S; Castro FA
Blood Cells Mol Dis; 2016 Jul; 59():25-30. PubMed ID: 27282563
[TBL] [Abstract][Full Text] [Related]
26. Role of JAK2 V617F mutation and aberrant expression of microRNA-143 in myeloproliferative neoplasms.
Benati M; Montagnana M; Danese E; De Matteis G; Veneri D; Paviati E; Guidi GC
Clin Chem Lab Med; 2015 Jun; 53(7):1005-11. PubMed ID: 25527813
[TBL] [Abstract][Full Text] [Related]
27. Crizotinib Has Preclinical Efficacy in Philadelphia-Negative Myeloproliferative Neoplasms.
Gurska LM; Okabe R; Schurer A; Tong MM; Soto M; Choi D; Ames K; Glushakow-Smith S; Montoya A; Tein E; Miles LA; Cheng H; Hankey-Giblin P; Levine RL; Goel S; Halmos B; Gritsman K
Clin Cancer Res; 2023 Mar; 29(5):943-956. PubMed ID: 36537918
[TBL] [Abstract][Full Text] [Related]
28. The JAK2 V617F mutational status and allele burden may be related with the risk of venous thromboembolic events in patients with Philadelphia-negative myeloproliferative neoplasms.
Borowczyk M; Wojtaszewska M; Lewandowski K; Gil L; Lewandowska M; Lehmann-Kopydłowska A; Kroll-Balcerzak R; Balcerzak A; Iwoła M; Michalak M; Komarnicki M
Thromb Res; 2015 Feb; 135(2):272-80. PubMed ID: 25559461
[TBL] [Abstract][Full Text] [Related]
29. JAK inhibitors: pharmacology and clinical activity in chronic myeloprolipherative neoplasms.
Treliński J; Robak T
Curr Med Chem; 2013; 20(9):1147-61. PubMed ID: 23317159
[TBL] [Abstract][Full Text] [Related]
30. [Our experience with detection of JAK2 mutations in paraffin-embedded trephine bone marrow biopsies of patients with chronic myeloproliferative disorders].
Burjanivová T; Marcinek J; Minárik G; Lasabová Z; Szépe P; Balhárek T; Vanochová A; Plank L
Cesk Patol; 2011 Jul; 47(3):115-7. PubMed ID: 21887928
[TBL] [Abstract][Full Text] [Related]
31. Acquired mutation of the tyrosine kinase JAK2V617F in Egyptian patients with myeloid disorders.
Ayad MW; Nafea D
Genet Test Mol Biomarkers; 2011; 15(1-2):17-21. PubMed ID: 21034166
[TBL] [Abstract][Full Text] [Related]
32. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
Hahm C; Huh HJ; Mun YC; Seong CM; Chung WS; Huh J
Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343
[TBL] [Abstract][Full Text] [Related]
33. [Detection and clinical significance of JAK2 mutation in 412 patients with chronic myeloproliferative neoplasms].
Chao HY; Fan Z; Zhang R; Shen YM; Chen W; Fei HR; Zhu ZL; Feng YF; Chen ZX; Xue YQ
Zhonghua Zhong Liu Za Zhi; 2009 Jul; 31(7):510-4. PubMed ID: 19950698
[TBL] [Abstract][Full Text] [Related]
34. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
[TBL] [Abstract][Full Text] [Related]
35. Current approaches to challenging scenarios in myeloproliferative neoplasms.
Zimran E; Hoffman R; Kremyanskaya M
Expert Rev Anticancer Ther; 2018 Jun; 18(6):567-578. PubMed ID: 29575945
[TBL] [Abstract][Full Text] [Related]
36. pSTAT5 and ERK exhibit different expression in myeloproliferative neoplasms.
Wiśniewska-Chudy E; Szylberg Ł; Dworacki G; Mizera-Nyczak E; Marszałek A
Oncol Rep; 2017 Apr; 37(4):2295-2307. PubMed ID: 28260027
[TBL] [Abstract][Full Text] [Related]
37. Insights into the Potential Mechanisms of JAK2V617F Somatic Mutation Contributing Distinct Phenotypes in Myeloproliferative Neoplasms.
Gou P; Zhang W; Giraudier S
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35162937
[TBL] [Abstract][Full Text] [Related]
38. JAK2 46/1 haplotype is associated with JAK2 V617F-positive myeloproliferative neoplasms in Japanese patients.
Tanaka M; Yujiri T; Ito S; Okayama N; Takahashi T; Shinohara K; Azuno Y; Nawata R; Hinoda Y; Tanizawa Y
Int J Hematol; 2013 Mar; 97(3):409-13. PubMed ID: 23430670
[TBL] [Abstract][Full Text] [Related]
39. The spectrum of JAK2-positive myeloproliferative neoplasms.
Kiladjian JJ
Hematology Am Soc Hematol Educ Program; 2012; 2012():561-6. PubMed ID: 23233635
[TBL] [Abstract][Full Text] [Related]
40. Myeloproliferative neoplasms: A decade of discoveries and treatment advances.
Tefferi A
Am J Hematol; 2016 Jan; 91(1):50-8. PubMed ID: 26492355
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]